Nrx pharmaceuticals announces positive data results from zyesami™ (aviptadil) expanded access protocol

Radnor, pa., june 15, 2021 /prnewswire/ -- nrx pharmaceuticals (nasdaq: nrxp), a clinical stage pharmaceutical company, today announced positive data from its zyesami™ (aviptadil) expanded access protocol (eap).

NRXP Ratings Summary

NRXP Quant Ranking